Page 7 - Dyslipidaemia_newsletter8_2024_Final
P. 7
REFLECTIONS
Dyslipidaemia
Dyslipidaemia Global Newsletter #8 2024
Specific interventions in individuals with high Lp(a) with the aim of reducing overall CV risk Dyslipidaemia
Healthy lifestyle Blood pressure reduction
• Stop smoking: no change • Therapy advised in guidelines: no change
• Plant-based foods that are considered healthy: no change
• Avoid higher weight: no change Diabetes control
• Physical exercise: no change • Therapy advised in guidelines: no change
Triglyceride and remnant cholesterol reduction
LDL cholesterol reduction
• High-intensity statin: no change • Therapy advised in guidelines: no change
• Ezetimibe: no change Reduction in weight
• PCSK9 inhibitor: decrease by 25% • Therapy advised in guidelines: no change
• Bempedoic acid: no change
• Apheresis: decrease by 35%
• Niacin: decrease by 25%
No change = no change in concentration of Lp(a).
The authors highlight specific interventions for individuals with high Lp(a) levels to mitigate their overall CV risk. While these
interventions do not directly lower Lp(a) concentrations (except for PCSK9i, apheresis, and niacin), they aim to reduce the absolute
risk of CVD by addressing other modifiable risk factors.
Several Lp(a)-lowering drugs are in development, with some showing substantial reductions (65%–98%) in Lp(a) levels. Large-scale
clinical trials are underway to assess their impact on cardiovascular outcomes.
Maximum achieved lipoprotein(a) reduction for five drugs in development
TABLE OF CONTENTS
